Literature DB >> 28707089

Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: response to Driessen et al.

K Kostev1, S Dombrowski2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28707089     DOI： 10.1007/s00198-017-4139-4

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  2 in total

1.  Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?

Authors:  J H M Driessen; L M Knapen; P P M M Geusens; J P W van den Bergh
Journal:  Osteoporos Int       Date:  2017-07-13       Impact factor: 4.507

2.  Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.

Authors:  S Dombrowski; K Kostev; L Jacob
Journal:  Osteoporos Int       Date:  2017-04-29       Impact factor: 4.507
  2 in total
  1 in total

Review 1.  Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.

Authors:  K Hidayat; X Du; B-M Shi
Journal:  Osteoporos Int       Date:  2019-05-27       Impact factor: 4.507
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.